Myoglobinuria following epsilon-aminocaproic acid (EACA) therapy. Case report.
Myoglobinuria developed in a patient with subarachnoid hemorrhage treated with a course of 1.43 kg of epsilon-aminocaproic acid (EACA) given over 41 days. Review of eight other cases with a variety of medical disorders shows that this effect occurs after at least 4 weeks of taking doses of a minimum of 24 gm EACA per day. The effect seems to be reversible if discovered early. This side-effect should provide impetus for restricting the duration of EACA therapy to periods under 28 days, in doses no higher than 24 gm/day.
D000614:Aminocaproates / Q000009:adverse effects*; D015119:Aminocaproic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009212:Myoglobinuria / Q000139:chemically induced* / Q000175:diagnosis; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy
D000614:Aminocaproates; D015119:Aminocaproic Acid